Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery
Key facts
- Where
- Phoenix, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Phoenix Children s HospitalPhoenix, United StatesContact: Kevin Engelhardt, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Phoenix Children's Hospital
- Trial code
- NCT04040452
- Record updated
- 12 August 2026
- Original description
The proposed study will be a prospective, randomized, double blind, placebo controlled trial to compare the use of a continuous infusion versus intermittent ketorolac on postoperative patients in the pediatric cardiovascular ICU. We intend to determine if the continuous infusion leads to a decreased utilization of opiates when compared to intermittent ketorolac.Read full original descriptionShow less
Continuous Infusion Versus Intermittent Ketorolac for Postoperative Pain Control in Pediatric Cardiac Surgery Patients
The proposed study will be a prospective, randomized, double blind, placebo controlled trial to compare the use of a continuous infusion versus intermittent ketorolac on postoperative patients in the pediatric cardiovascular ICU. We intend to determine if the continuous infusion leads to a decreased utilization of opiates when compared to intermittent ketorolac.
Inclusion: All patients aged 3 months to 4 years 11months admitted post operatively to the CVICU during the time period in which the study will be ongoing; Initiation of study medication within the first 12-24 hours post-operatively; The cardiovascular attending of record after review of the intraoperative course and post-operative laboratories determines the patient will receive Ketorolac for pain control.
Exclusion: Requiring mechanical circulatory support (ECMO) or continuous renal replacement therapy (CRRT) within the first 48 hours post-operatively; History of allergy or sensitivity reaction to ketorolac or any NSAID medications; Orthotopic heart transplantation; Clinically significant bleeding; Patients with known pre-operative medical renal disease, renal transplantation history, congenital or acquired renal abnormality or deformity; Patients that have acute kidney injury, as defined by the letter "I" in the pRIFLE criteria.